NovaMedica
NovaMedica is a Russian pharmaceutical company that registers, manufactures, and distributes three proprietary branded drugs (Relonova for migraine, Difendum for pain, Levroso Long for insomnia) via GMP-certified production and domestic pharmacy networks in Russia.
- Company typePrivate
- Founded2012
- HeadquartersMoscow, Russia
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What NovaMedica does
NovaMedica is a Russian pharmaceutical company founded in 2012 and headquartered in Moscow, operating exclusively in the domestic Russian market. The company commercializes innovative medical products through a full-cycle model that encompasses product registration, GMP-certified manufacturing, and sales via pharmaceutical distribution networks and pharmacy channels.
NovaMedica's product portfolio consists of three proprietary branded pharmaceutical products. Relonova is a Rizatriptan-based treatment for migraine headaches. Difendum is a Diclofenac potassium-based anti-inflammatory analgesic for pain syndromes of various localization. Levroso Long is a fixed-combination insomnia treatment containing Diphenhydramine and Melatonin. All three products are registered brands in the Russian market, though the underlying active pharmaceutical ingredients are generic molecules available from multiple manufacturers. The core technology is GMP (Good Manufacturing Practice) certified pharmaceutical production, which provides regulatory compliance for commercialization in Russia.
The company operates a sales-led go-to-market model, generating revenue through one-time pharmaceutical product sales distributed through Russian pharmacy networks and healthcare providers. Customer access is facilitated through direct contact channels (phone and email) during business hours. NovaMedica serves patient populations with migraine, pain syndromes, and insomnia as its primary use cases. The firm employs 501-1,000 staff and is privately held with no disclosed parent company, institutional investors, or funding rounds in the available data.
NovaMedica firmographics
Firmographics- Name
- NovaMedica
- Legal name
- NovaMedica
- Website
- https://novamedica.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- NovaMedica is a Russian pharmaceutical company that registers, manufactures, and distributes three proprietary branded drugs (Relonova for migraine, Difendum for pain, Levroso Long for insomnia) via GMP-certified production and domestic pharmacy networks in Russia.
- Ownership category
- akta.pro rank
NovaMedica industry classification
Industry- Product category
- Prescription Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where NovaMedica is headquartered
LocationHeadquarters
- HQ city
- Moscow
- HQ country
- Russia
- HQ region
- Europe
Offices1 record
Markets served
NovaMedica business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Others
Revenue model
- Pharmaceutical Product Sales: NovaMedica generates revenue through the sale of proprietary pharmaceutical products including treatments for migraine, pain syndromes, and insomnia. The company handles product registration, manufacturing under GMP standards, and commercial distribution within Russia.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
NovaMedica product offering
Product offeringCore offering
NovaMedica is a Russian pharmaceutical company that promotes and commercializes proprietary pharmaceutical products within Russia. It handles the full lifecycle from product registration and GMP-certified manufacturing to commercial sales. Its current portfolio consists of three drugs: Relonova (Rizatriptan-based migraine treatment), Difendum (Diclofenac potassium-based pain syndrome treatment), and Levroso Long (Diphenhydramine and Melatonin fixed-combination insomnia treatment).
Product overview
NovaMedica is a Russian pharmaceutical company that promotes innovative medical products and technologies in Russia, including registration, GMP production, and sales. The company offers a portfolio of three pharmaceutical products: Relonova (for migraine treatment with Risatriptan), Difendum (for pain syndromes with Diclofenac potassium), and Levroso Long (for insomnia treatment with a fixed combination of Diphenhydramine and melatonin).
Differentiator
Problem solved
Functional benefit
Brands
- Relonova (Релонова): Migraine treatment drug containing Rizatriptan
- Difendum (Дифендум)
- Levroso Long (Левросо Лонг)
Products and services
- Relonova (Релонова) Proprietary branded pharmaceutical for the treatment of migraine headaches, containing Rizatriptan as the active ingredient. Distributed through pharmaceutical wholesalers and pharmacy chains in Russia.
- Difendum (Дифендум) Proprietary branded pharmaceutical for the treatment of pain syndromes of various localization, containing Diclofenac potassium as the active ingredient. Distributed through pharmaceutical wholesalers and pharmacy chains in Russia.
- Levroso Long (Левросо® Лонг) Proprietary branded fixed-combination pharmaceutical for the treatment of insomnia, containing Diphenhydramine and Melatonin as active ingredients. Distributed through pharmaceutical wholesalers and pharmacy chains in Russia.
Companies that use NovaMedica
Customer profileSegments3 records
Ideal customer profiles1 record
NovaMedica technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
NovaMedica partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights3 records
NovaMedica competitors and assessment
Company assessmentDirect peers
- Pharmstandard: One of the largest Russian pharmaceutical manufacturers with a broad branded generics portfolio spanning CNS, pain, and other therapeutic areas. Directly comparable as a domestic Russian pharma producing and commercializing branded products in overlapping indications.
- Valenta Pharm: Russian pharmaceutical company focused on branded prescription and OTC products including CNS and pain therapies. Comparable in business model, Russian-market focus, and branded product strategy.
- OTCPharm: Russian pharma manufacturer and marketer of branded OTC and prescription products. Overlaps with NovaMedica on branded product strategy and Russian market distribution.
- Veropharm: Russian pharmaceutical manufacturer with GMP production and a portfolio of branded generics. Comparable as a domestic pharma with integrated manufacturing and sales operations.
- Polysan: Russian pharmaceutical manufacturer producing branded products including CNS therapies. Similar in size, GMP manufacturing, and Russian-market focus.
Broad incumbents
- R-Pharm: Major Russian pharmaceutical company with a much broader portfolio across multiple therapeutic areas. Comparable as a Russian pharma incumbent but operates at significantly larger scale with broader R&D.
- Biocad: Large Russian biopharmaceutical company with manufacturing and sales capabilities. Comparable as a Russian pharma manufacturer, though Biocad focuses more on biologics and biosimilars.
Regional players
- Stada Arzneimittel: European generics and specialty pharma company with established operations in Russia and CIS. Comparable as a producer of branded generics with significant Russian-market presence.
- Gedeon Richter: Hungarian-headquartered pharma with substantial Russian operations and a CNS-heavy portfolio. Comparable in therapeutic area overlap (CNS) and Russian-market exposure.
- Krka: Slovenian generic pharma manufacturer with a strong presence in Russia/CIS markets. Comparable as a generics manufacturer with meaningful Russian revenue exposure.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
NovaMedica social profiles
Digital presenceNovaMedica financial estimates
Financial estimateRevenue estimate
Valuation estimate
NovaMedica leadership team
Management profileNumber of profiles
Profiles1 record
NovaMedica funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NovaMedica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NovaMedica
What does NovaMedica do?
NovaMedica is a Russian pharmaceutical company that promotes and commercializes proprietary pharmaceutical products within Russia. It handles the full lifecycle from product registration and GMP-certified manufacturing to commercial sales. Its current portfolio consists of three drugs: Relonova (Rizatriptan-based migraine treatment), Difendum (Diclofenac potassium-based pain syndrome treatment), and Levroso Long (Diphenhydramine and Melatonin fixed-combination insomnia treatment).
Is NovaMedica a public or private company?
NovaMedica is a private company. It is classified as unknown and is currently operating.
When was NovaMedica founded?
NovaMedica was founded in 2012. It employs 501 to 1,000 people.
Where is NovaMedica based?
NovaMedica is headquartered in Moscow, Russia, in the Europe region.
How does NovaMedica make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are NovaMedica's main competitors?
Direct peers on record are Pharmstandard, Valenta Pharm, OTCPharm, Veropharm and Polysan. Broad incumbents are R-Pharm and Biocad. Regional players are Stada Arzneimittel, Gedeon Richter and Krka.
Does NovaMedica have an API?
No public API is recorded for NovaMedica.
What industry is NovaMedica in?
NovaMedica's product category is Prescription Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.